Huang Xiuliang, Wang Kailiang, Han Jing, Chen Xiumei, Wang Zhenglin, Wu Tianlun, Yu Bo, Zhao Feng, Wang Xinjuan, Li Huijuan, Xie Zhi, Zhu Xiaotian, Zhong Wenge, Ren Xiaoming
Regor Therapeutics Group, Shanghai 201210, China.
Regor Therapeutics Group, Shanghai 201210, China.
Structure. 2024 Jul 11;32(7):907-917.e7. doi: 10.1016/j.str.2024.03.007. Epub 2024 Apr 5.
PI3Kα is a lipid kinase that phosphorylates PIP2 and generates PIP3. The hyperactive PI3Kα mutation, H1047R, accounts for about 14% of breast cancer, making it a highly attractive target for drug discovery. Here, we report the cryo-EM structures of PI3Kα bound to two different allosteric inhibitors QR-7909 and QR-8557 at a global resolution of 2.7 Å and 3.0 Å, respectively. The structures reveal two distinct binding pockets on the opposite sides of the activation loop. Structural and MD simulation analyses show that the allosteric binding of QR-7909 and QR-8557 inhibit PI3Kα hyper-activity by reducing the fluctuation and mobility of the activation loop. Our work provides a strong rational basis for a further optimization and development of highly selective drug candidates to treat PI3Kα-driven cancers.
PI3Kα是一种脂质激酶,可使PIP2磷酸化并生成PIP3。超活性PI3Kα突变体H1047R约占乳腺癌的14%,使其成为极具吸引力的药物研发靶点。在此,我们报告了PI3Kα与两种不同变构抑制剂QR - 7909和QR - 8557结合的冷冻电镜结构,整体分辨率分别为2.7 Å和3.0 Å。这些结构揭示了在激活环相对两侧的两个不同结合口袋。结构和分子动力学模拟分析表明,QR - 7909和QR - 8557的变构结合通过降低激活环的波动和流动性来抑制PI3Kα的过度活性。我们的工作为进一步优化和开发用于治疗PI3Kα驱动癌症的高选择性候选药物提供了有力的理论依据。